Indeed, the authors hypothesize that the parallel administration of PKCβ inhibitor, along with APDs, could prevent or delay the development of obesity and obesity-related disorders, introducing the hypothesis that the inhibition of PKCβ could be therapeutically useful in conjunction with APDs (Figure 2). This evidence concerns the gene PRKCB and obesity disorder.